ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1043

A Prospective Study on Early Diagnosis of Inflammatory Rheumatic Diseases Using an Enhanced Online Questionnaire System (RhePort 1.3)

Cay von Der Decken1, Stefan Kleinert2, Matthias Englbrecht3, Kirsten Karberg4, Georg Gauler5, Susanna Spaethling-Mestekemper6, Christoph Kuhn7, Wolfgang Vorbrueggen8, Martin Welcker9 and Peter Bartz-Bazzanella10, 1Klinik für Internistische Rheumatologie, Rhein-Maas-Klinik Wuerselen, Würselen, 2Praxisgemeinschaft Rheumatologie - Nephrologie (PGRN), Erlangen, Germany, 3Freelance Healthcare Data Scientist, Eckental, 4Rheumatologisches Versorgungszentrum Steglitz, Berlin, Germany, 5rheumapraxis, Osnabrück, Germany, 6Rheumapraxis Muenchen, Muenchen, Germany, 7Praxis für Rheumatologie, Karlsruhe, Germany, 8Verein zur Foerderung der Rheumatologie e.V, Wuerselen, Germany, 9Medizinisches Versorgungszentrum für Rheumatologie Dr. M. Welcker GmbH, Planegg, Germany, 10Rhein-Maas Klinikum, Wuerselen, Germany

Meeting: ACR Convergence 2024

Keywords: Access to care, Health Care, Health Services Research

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Health Services Research – ACR/ARP Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: The RhePort system, accessible via “www.RhePort.de” and featuring an integrated questionnaire with a specialized algorithm, aims to facilitate the early diagnosis of inflammatory rheumatic diseases (IRD). This system prioritizes access for primary care physicians and patients to a first consultation with a rheumatologist, enabling earlier diagnosis and quicker initiation of specific therapies, such as DMARDs and biologics. This project evaluates the upgraded version, RhePort 1.3, using a newly designed questionnaire and assesses its performance.

Methods: This prospective study included patients completing the RhePort questionnaire online or during their first rheumatological appointment. The RhePort system generated a score based on the responses, which was followed by a rheumatological consultation to confirm or exclude inflammatory IRD. The largest subgroups of patients diagnosed with IRDs (20 patients each at least) were analyzed regarding their mean RhePort score compared to the group of patients  also referred to participating study centers but ultimately diagnosed not having IRD.

Results: Among 614 diagnoses (table 1), no rheumatic disease was found in 63.4%. Patients with no inflammatory rheumatic disease (IRD) had a mean RhePort score of 1.42 (95% CI: 1.30-1.55). Higher mean scores were seen in those diagnosed with rheumatoid arthritis (RA) [2.15 (95% CI: 1.87-2.43)] and polymyalgia rheumatica (PMR) [2.12 (95% CI: 1.55-2.69)]. Corresponding effect sizes compared to patients without IRD (moderate effect: d > 0.5) are displayed in figure 1. Axial spondyloarthritis (axSpA) had a mean score of 2.07 (95% CI: 1.40-2.75), and patients with psoriatic arthritis (PsA) of 1.74 (95% CI: 1.41-2.08). See table 2 for further details.

Conclusion: The upgraded RhePort 1.3 system, significantly aids in detecting patients with (IRD), ensuring quicker access to appropriate rheumatological care and facilitating timely intervention. The RhePort system’s potential for broader application in clinical practice warrants further investigation to optimize its diagnostic algorithms and expand its use in diverse healthcare settings.

Supporting image 1

Table 1: Complete Diagnoses, n = 614

Supporting image 2

Figure 1: Average RhePORT Score. Effect Sizes RA, PsA, PMR, and axSPA compared to no IRD.

Supporting image 3

Table 2: Diagnoses groups for analyzes, n = 566 with mean RhePORT Score, Age, Sex.


Disclosures: C. von Der Decken: AbbVie/Abbott, 12, Versorungssymposium 2024, Galapagos/Alphasigma, 12, DGRh-Kongress 2023 and 2024; S. Kleinert: AbbVie/Abbott, 6, Chugai, 6, Novartis, 5, 6; M. Englbrecht: AbbVie, 2, Sanofi, 6; K. Karberg: None; G. Gauler: AbbVie/Abbott, 6, Eli Lilly, 1, Novartis, 6, UCB, 6; S. Spaethling-Mestekemper: AbbVie/Abbott, 6, Boehringer-Ingelheim, 6, Eli Lilly, 6, GlaxoSmithKlein(GSK), 6, Janssen, 6, Novartis, 6, UCB, 6; C. Kuhn: None; W. Vorbrueggen: None; M. Welcker: AbbVie/Abbott, 1, 5, 6, Boehringer-Ingelheim, 1, 5, 6, Eli Lilly, 1, 6, Gilead, 1, 6, Novartis, 1, 5, 6; P. Bartz-Bazzanella: AbbVie/Abbott, 6, Boehringer-Ingelheim, 6, Eli Lilly, 6, Novartis, 5, 6.

To cite this abstract in AMA style:

von Der Decken C, Kleinert S, Englbrecht M, Karberg K, Gauler G, Spaethling-Mestekemper S, Kuhn C, Vorbrueggen W, Welcker M, Bartz-Bazzanella P. A Prospective Study on Early Diagnosis of Inflammatory Rheumatic Diseases Using an Enhanced Online Questionnaire System (RhePort 1.3) [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/a-prospective-study-on-early-diagnosis-of-inflammatory-rheumatic-diseases-using-an-enhanced-online-questionnaire-system-rheport-1-3/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-prospective-study-on-early-diagnosis-of-inflammatory-rheumatic-diseases-using-an-enhanced-online-questionnaire-system-rheport-1-3/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology